close
close

Tag: biopharmaceutical company

European Commission decision to approve the pediatric use of the antifungal Cresemba® (isavuconazole) and to extend market exclusivity triggers milestone payment of CHF 10 million to Basilea

Posted on | Posted on Jasper | Leave a Comment on European Commission decision to approve the pediatric use of the antifungal Cresemba® (isavuconazole) and to extend market exclusivity triggers milestone payment of CHF 10 million to Basilea
European Commission decision to approve the pediatric use of the antifungal Cresemba® (isavuconazole) and to extend market exclusivity triggers milestone payment of CHF 10 million to Basilea

Basilea Pharmaceutica AG, Allschwil Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 27, 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), a biopharmaceutical company focused on the needs of patients with severe bacterial and fungal infections, today announced that the European Commission (EC) has expanded the indications for the antifungal Cresemba.® (isavuconazole) for […]

Chief Business Officer Gregory Weinhoff sells 30,000 shares of Centessa …

Posted on | Posted on Jasper | Leave a Comment on Chief Business Officer Gregory Weinhoff sells 30,000 shares of Centessa …
Chief Business Officer Gregory Weinhoff sells 30,000 shares of Centessa …

On August 23, 2024, Gregory Weinhoff, the Chief Business Officer of Centessa Pharmaceuticals PLC (NASDAQ:CNTA), performed a significant transaction by selling 30,000 shares of the company’s stock. The sale was documented in a recent SEC filing. Following this transaction, the insider now owns 223,369 shares of Centessa Pharmaceuticals PLC. Centessa Pharmaceuticals PLC, trading under the […]

CFO Mark Hahn sells 400,000 shares of Verona Pharma PLC (VRNA)

Posted on | Posted on Jasper | Leave a Comment on CFO Mark Hahn sells 400,000 shares of Verona Pharma PLC (VRNA)
CFO Mark Hahn sells 400,000 shares of Verona Pharma PLC (VRNA)

Mark Hahn, the Chief Financial Officer of Verona Pharma PLC (NASDAQ:VRNA), conducted a significant transaction on August 13, 2024, in which the insider sold 400,000 shares of the company’s stock. The sale was documented in a recent SEC filing. Following this transaction, the insider now owns 14,939,688 shares of Verona Pharma PLC. Verona Pharma PLC […]

Chief Scientific Officer Stephen Betz sells 3,000 shares of Crinetics …

Posted on | Posted on Jasper | Leave a Comment on Chief Scientific Officer Stephen Betz sells 3,000 shares of Crinetics …
Chief Scientific Officer Stephen Betz sells 3,000 shares of Crinetics …

According to a recent SEC filing, Chief Scientific Officer Stephen Betz sold 3,000 shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) on August 12, 2024. Following this transaction, the insider now owns 72,611 shares of the company. Crinetics Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine […]

Chief People Strategy Officer Schaeffer Orlov S Nicole sells shares to Insmed Inc …

Posted on | Posted on Jasper | Leave a Comment on Chief People Strategy Officer Schaeffer Orlov S Nicole sells shares to Insmed Inc …
Chief People Strategy Officer Schaeffer Orlov S Nicole sells shares to Insmed Inc …

On August 12, 2024, Schaeffer Orlov S Nicole, Chief People Strategy Officer, sold 9,469 shares of Insmed Inc (NASDAQ:INSM) at a price of $72.49 per share. The transaction was documented in a recent SEC filing. Following this sale, the insider now owns 100,100 shares of the company. Insmed Inc is a global biopharmaceutical company focused […]